Evidence map›Paper›PMID 30969400›Full record

ReviewAdvances in experimental medicine and biology2021

Role of Tumor Specific niche in Colon Cancer Progression and Emerging Therapies by Targeting Tumor Microenvironment.

Antara Banerjee, Yashna Chabria, Rajesh Kanna N R, Janani Gopi, Praveen Rowlo, Xiao-Feng Sun, Surajit Pathak

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
10.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 44 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Antara BanerjeeFaculty of Allied Health Sciences, Chettinad Academy of Research and Education (CARE) and Chettinad Hospital and Research Institute (CHRI), Kelambakkam, Tamil Nadu, India. antarabanerjee@chettinadhealthcity.com.
Yashna ChabriaFaculty of Allied Health Sciences, Chettinad Academy of Research and Education (CARE) and Chettinad Hospital and Research Institute (CHRI), Kelambakkam, Tamil Nadu, India.
Rajesh Kanna N RDepartment of Pathology, Faculty of Medicine, Chettinad Academy of Research & Education, Kelambakkam, Tamil Nadu, India.
Janani GopiFaculty of Allied Health Sciences, Chettinad Academy of Research and Education (CARE) and Chettinad Hospital and Research Institute (CHRI), Kelambakkam, Tamil Nadu, India.
Praveen RowloFaculty of Allied Health Sciences, Chettinad Academy of Research and Education (CARE) and Chettinad Hospital and Research Institute (CHRI), Kelambakkam, Tamil Nadu, India.
Xiao-Feng SunDepartment of Oncology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
Surajit PathakFaculty of Allied Health Sciences, Chettinad Academy of Research and Education (CARE) and Chettinad Hospital and Research Institute (CHRI), Kelambakkam, Tamil Nadu, India.
Chettinad Academy of Research and Education · INLinköping University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer is the third most common form of cancer worldwide leading to escalating mortality rates and mainly includes hereditary, sporadic and colitis-associated cancer development. The escalated mortality rates is due to the limited treatment options as this form of cancer is usually not easy to diagnose in its early stages and are highly invasive leading to rapid metastasis of the malignant cells to the neighbouring tissue. In order to combat this limitation several chemotherapeutic regimens are now being combined with targeted therapies after the knowledge acquired on the inevitable effects of the tumor microenvironment on the colon cancer growth and progress. The colon tumor niche mainly consists of a large mass of tumor cells along with various immune cells, inflammatory cells, tumor macrophages and fibroblasts that infiltrate the tumor as it is a site of predominant inflammation. Among cells of the microenvironment, mesenchymal stem cells (MSCs) exhibiting ability to evolve into cancer associated fibroblasts (CAFs) have recently generated a major interest in the field. The physiological state of the tumor microenvironment is closely connected to discrete steps of tumorigenesis. The colon cancer cells elicit various factors with their direct interaction with MSCs or via paracrine fashion, which modulate these cells to promote cancer instead of performing their innate function of abating cancer progression. This review intends to highlight the necessity to exploit the cellular landscape of tumor microenvironment of colon cancer and a detailed understanding of the interactions between tumor epithelial cells and their stromal/inflammatory elements will aid in future perspectives for designing therapeutic regimens targeting tumor microenvironment to improve the clinical outcome of colon cancer.

Indexed as

Cancer-Associated FibroblastsColonic NeoplasmsMesenchymal Stem CellsHumansTumor MicroenvironmentColon cancerCytokinesMesenchymal stem cellsMetastasismicroRNAsTargeted therapyTumor niche

Identifiers

PMID30969400
OpenAlexW2940174050

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.